https://www.selleckchem.com/pr....oducts/Sunitinib-Mal
Main analyses cost-effectiveness, including incremental cost-effectiveness ratio (ICER) and a cost-effectiveness acceptability curve (CEAC); and ROI analyses with use of the human capital method. Results N = 324 participants were analyzed. The results show that VR+ was cost-effective compared to VR mean cost savings of €820 per 0.012 QALY gained. CEAC suggests probability of VR+ being cost-effective is 0.91 for thresholds of €20.000 and higher. The mean ROI of VR+ for employers was 38%. Conclusion It was concluded
Like
Comment
Share
